● Recruiting

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Condition: Unresectable Biliary Tract Carcinoma · Sponsor: Henan Cancer Hospital

PhasePhase 2

Planned participants63

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

This study is designed to combine anti-angiogenic drugs on the basis of PD-L1+ gemcitabine/cisplatin, hoping to further improve the curative effect of advanced BTC treatment and provide more choices for first-line treatment of BTC in China.

This description comes directly from the study's public registry record.

Talk to the study team

Ying Liu, MD · +86 137 8360 4602 · yaya7207@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

HeNan

Zhengzhou, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06749730